Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

About The Institute

The Institute for Tuberculosis Research (ITR), located at the University of Illinois at Chicago, is a drug discovery research facility working on the development of new drugs to combat an old, but still evolving global public health threat. The ITR is unique in that it brings an industrial model of drug discovery into an academic environment. In Chicago we have assembled all of the necessary components - high throughput screening, microbiology, molecular biology, medicinal chemistry, natural products chemistry, drug metabolism, pharmacokinetics and toxicology - on one campus to maximize efficiency and communication. In addition to in-house discovery projects, we also collaborate with many public and private sector institutions around the world to facilitate their efforts towards the same goal. 

Located in Chicago, our members come from Brazil, China, Germany, India, Iran, Japan, Korea, Poland, Russia and the U.S. Our group includes 4 primary faculty, 7 affiliate faculty, 2 adjunct faculty, BS, MS and PhD staff scientists, and administrative staff. We occupy 4,500 sq. ft. of labs and offices in the College of Pharmacy at the University of Illinois at Chicago.

Our research is supported by the Global Alliance for TB Drug Development, the National Institutes of Health, fee-for-service arrangements from industry, and a patent royalty stream. Our annual budget consists of over one million dollars in grants and contracts.